2. Vitamin D Related/Nuclear Receptor Metabolic Enzyme/Protease
  3. Glycosidase Estrogen Receptor/ERR Phosphodiesterase (PDE)
  4. Pinoresinol 4-O-β-D-glucopyranoside

Pinoresinol 4-O-β-D-glucopyranoside  (Synonyms: (+)-Pinoresinol 4-O-β-D-glucopyranoside)

Cat. No.: HY-N2168 Purity: 99.89%
SDS
COA
Handling Instructions Technical Support

Pinoresinol 4-O-β-D-glucopyranoside is an orally active α-glucosidase inhibitor, with an IC50 of 48.13 μg/mL. Pinoresinol 4-O-β-D-glucopyranoside binds to estrogen receptors. Pinoresinol 4-O-β-D-glucopyranoside inhibits phosphodiesterase. Pinoresinol 4-O-β-D-glucopyranoside exhibits various activities such as antioxidant, anti-inflammatory, anti-hyperglycemic, hepatoprotective and anti-epileptic effects.

For research use only. We do not sell to patients.

Pinoresinol 4-O-β-D-glucopyranoside Chemical Structure

Pinoresinol 4-O-β-D-glucopyranoside Chemical Structure

CAS No. : 69251-96-3

Size Price Stock Quantity
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Pinoresinol 4-O-β-D-glucopyranoside:

Pinoresinol 4-O-β-D-glucopyranoside Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Pinoresinol 4-O-β-D-glucopyranoside

View All Estrogen Receptor/ERR Isoform Specific Products:

View All Isoforms
Estrogen receptor ERα ERβ ERRα ERRβ ERRγ

View All Phosphodiesterase (PDE) Isoform Specific Products:

View All Isoforms
PDE1 PDE2 PDE3 PDE4 PDE5 PDE6 PDE7 PDE9 PDE10 PDE11 PDE12 PDE8 Autotaxin

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Pinoresinol 4-O-β-D-glucopyranoside is an orally active α-glucosidase inhibitor, with an IC50 of 48.13 μg/mL. Pinoresinol 4-O-β-D-glucopyranoside binds to estrogen receptors. Pinoresinol 4-O-β-D-glucopyranoside inhibits phosphodiesterase. Pinoresinol 4-O-β-D-glucopyranoside exhibits various activities such as antioxidant, anti-inflammatory, anti-hyperglycemic, hepatoprotective and anti-epileptic effects[1][2][3][4][5][6][7][8].

In Vitro

Pinoresinol 4-O-β-D-glucopyranoside (0.1 μM-0.1 mM; 24 h) activates estrogen receptor (ER)-dependent transcription of both transfected and endogenous target genes in Hela cells and MCF-7 cells, and induces pS2 mRNA expression in MCF-7 cells in a dose-dependent manner[1].
Pinoresinol 4-O-β-D-glucopyranoside shows no inhibitory activity against A/PR/8/34 (H1N1) virus in MDCK cells[2].
Pinoresinol 4-O-β-D-glucopyranoside shows promising antioxidant activity with an IC50 of 34.5 μg/mL in the ABTS assay[4].
Pinoresinol 4-O-β-D-glucopyranoside exhibits a potent α-glucosidase inhibition, with an IC50 of 48.13 μg/mL[4].
Pinoresinol 4-O-β-D-glucopyranoside (2.5-150 μg/mL) displays a substantial antioxidant activity in the DPPH scavenging capacity assay, with an IC50 of 44.2 μg/mL and a TAC of 737.7 μmol/g[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pinoresinol 4-O-β-D-glucopyranoside Related Antibodies

Cell Viability Assay[1]

Cell Line: MCF-7 cells, MDA-MB-231 cells
Concentration: 1, 10, 100 μM
Incubation Time: 5 days
Result: Enhanced the proliferation of MCF-7 cells.
Inhibited the proliferation of MDA-MB-231 cells at doses that influenced MCF-7 cells.
In Vivo

Pinoresinol 4-O-β-D-glucopyranoside (50 mg/kg; p.o.; 20 days for hepatoprotective activity test, 10 days for antihyperglycaemic activity test) exhibits hepatoprotective activity by lowering AST and ALT levels in CCl4 (HY-Y0298)-induced hepatotoxicity mice, and shows antihyperglycaemic activity by causing a prominent decline in serum glucose level and a promising elevation in insulin level in Streptozotocin (HY-13753)-treated mice[4].
Pinoresinol 4-O-β-D-glucopyranoside (25-50 mg/kg; p.o.; twice with the second dose 1 h before pilocarpine injection) ameliorates the seizures in a dose-dependent manner in lithium/Pilocarpine (HY-B0726A)-induced epileptic seizures rats, manifested by retarding seizure onset, reducing the number of rats developing seizures, and enhancing the survival of animals after seizure exposure[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Swiss albino mice (weight: 27-30 g), CCl4-induced hepatotoxicity model and Streptozotocin-induced hyperglycaemia model[4]
Dosage: 50 mg/kg b.w.
Administration: Oral gavage (p.o.), 20 days in the hepatotoxicity experiment; 10 days in the hyperglycaemia experiment
Result: Led to a 33.94% decline in AST, a 3.01% decline in ALT, and a 49.96% decline in LPO levels (in the CCl4-induced hepatotoxicity model).
Significantly enhanced CAT, SOD, and TAS levels by 130%, 90.45%, and 61.39% respectively compared to the CCl4-treated group (in the CCl4-induced hepatotoxicity model).
Caused a 37.83% reduction in serum glucose level and a 25.37% increase in insulin level (in the Streptozotocin-induced hyperglycaemia model).
Reduced lipid peroxide levels by 51.77% and increased serum levels of CAT, SOD, and TAS by 93.02%, 70.79%, and 101.90%, respectively (in the Streptozotocin-induced hyperglycaemia model).
Molecular Weight

520.53

Formula

C26H32O11
CAS No.
Appearance

Solid

Color

White to light yellow

SMILES

COC(C=C1[C@@H]2[C@](CO[C@@H]3C4=CC(OC)=C(O)C=C4)([H])[C@]3([H])CO2)=C(C=C1)O[C@@H]([C@@H]([C@@H](O)[C@@H]5O)O)O[C@@H]5CO
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (192.11 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.9211 mL 9.6056 mL 19.2112 mL
5 mM 0.3842 mL 1.9211 mL 3.8422 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (4.80 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (4.80 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.89%

SDS (252 KB)

COA (260 KB) HNMR (282 KB) LCMS (261 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.9211 mL 9.6056 mL 19.2112 mL 48.0280 mL
5 mM 0.3842 mL 1.9211 mL 3.8422 mL 9.6056 mL
10 mM 0.1921 mL 0.9606 mL 1.9211 mL 4.8028 mL
15 mM 0.1281 mL 0.6404 mL 1.2807 mL 3.2019 mL
20 mM 0.0961 mL 0.4803 mL 0.9606 mL 2.4014 mL
25 mM 0.0768 mL 0.3842 mL 0.7684 mL 1.9211 mL
30 mM 0.0640 mL 0.3202 mL 0.6404 mL 1.6009 mL
40 mM 0.0480 mL 0.2401 mL 0.4803 mL 1.2007 mL
50 mM 0.0384 mL 0.1921 mL 0.3842 mL 0.9606 mL
60 mM 0.0320 mL 0.1601 mL 0.3202 mL 0.8005 mL
80 mM 0.0240 mL 0.1201 mL 0.2401 mL 0.6003 mL
100 mM 0.0192 mL 0.0961 mL 0.1921 mL 0.4803 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Pinoresinol 4-O-β-D-glucopyranoside Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Pinoresinol 4-O-β-D-glucopyranoside69251-96-3(+)-Pinoresinol 4-O-β-D-glucopyranosideGlycosidaseEstrogen Receptor/ERRPhosphodiesterase (PDE)furofuran typelignanscAMPphosphodiesteraseantihyperglycaemichepatotoxicityHelaInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Pinoresinol 4-O-β-D-glucopyranoside
Cat. No.:
HY-N2168
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.